![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, August 06, 2010 12:08:09 AM
--
The process for Evaluation of Automatic Class III Designation (also known as the de novo classification process) is meant to serve as a regulatory pathway for novel devices that cannot be cleared through the 510(k) process because they lack a clear predicate, but whose risks do not warrant a premarket approval (PMA) level of review. As currently implemented, the de novo classification process tends to be associated with lengthy review timeframes and nontransparent data requirements, making it an impractical path to market for many device developers. The 510(k) Working Group recommends that CDRH make major reforms in our implementation of the de novo process, including steps to streamline the process and clarify the Center’s evidentiary expectations for de novo requests.
---
http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM220782.pdf
IS_guru
Kona Gold Beverages, Inc. Nears Completion of Reverse Merger with New Candidate • KGKG • Aug 12, 2024 10:00 AM
Maybacks Global Entertainment and DigiTrax Entertainment Sign Agreement to Broadcast "Karaoke Cloud" on iDreamCTV • AHRO • Aug 12, 2024 8:45 AM
HealthLynked Partners with RxSpark to Enhance Medication Access and Management for Patients • HLYK • Aug 12, 2024 8:00 AM
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM